PMID- 30271115
OWN - NLM
STAT- MEDLINE
DCOM- 20181224
LR  - 20220330
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 12
DP  - 2018
TI  - The role of hypoxia-inducible factor stabilizers in the treatment of anemia in 
      patients with chronic kidney disease.
PG  - 3003-3011
LID - 10.2147/DDDT.S175887 [doi]
AB  - INTRODUCTION: The purpose of this study was to analyze the effects of 
      hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent 
      (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients. METHODS: 
      Published studies were extracted from PubMed, China Biological Medicine Database 
      (CBM), Wanfang database, and Cochrane Library on March 10, 2018, and relevant 
      studies were pooled and included in a meta-analysis. Data on hemoglobin (Hb), 
      ferritin, and hepcidin levels, total iron-binding capacity (TIBC), and incidence 
      of adverse events (AEs) were extracted and pooled using Review Manager Version 
      5.3. RESULTS: Data from nine selected studies were extracted. Meta-analysis of 
      the included studies showed that HIF stabilizers reduced ferritin and hepcidin 
      levels and increased Hb level and TIBC in NDD-CKD patients. However, HIF 
      stabilizers only increased TIBC, and did not affect ferritin, hepcidin, and Hb 
      levels in DD-CKD patients. Furthermore, no notable differences in AEs and severe 
      AEs between NDD-CKD and DD-CKD patients were detected. CONCLUSION: HIF 
      stabilizers are effective for the treatment of anemia in NDD-CKD patients and 
      safe for short-term use.
FAU - Zhong, Hongzhen
AU  - Zhong H
AD  - Department of Nephrology, The Second Affiliated Hospital, Shantou University 
      Medical College, Shantou, China, zhoutb@aliyun.net.
FAU - Zhou, Tianbiao
AU  - Zhou T
AD  - Department of Nephrology, The Second Affiliated Hospital, Shantou University 
      Medical College, Shantou, China, zhoutb@aliyun.net.
FAU - Li, Hongyan
AU  - Li H
AD  - Department of Nephrology, Huadu District People's Hospital of Guangzhou, Southern 
      Medical University, Guangzhou, China.
FAU - Zhong, Zhiqing
AU  - Zhong Z
AD  - Department of Nephrology, The Second Affiliated Hospital, Shantou University 
      Medical College, Shantou, China, zhoutb@aliyun.net.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180918
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 138391-32-9 (Aryl Hydrocarbon Receptor Nuclear Translocator)
RN  - EC 1.14.11.29 (Hypoxia-Inducible Factor-Proline Dioxygenases)
SB  - IM
MH  - Anemia/*drug therapy/metabolism
MH  - Aryl Hydrocarbon Receptor Nuclear Translocator/*metabolism
MH  - Enzyme Inhibitors/*pharmacology/*therapeutic use
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
MH  - Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors
MH  - Protein Stability/drug effects
MH  - Renal Insufficiency, Chronic/*drug therapy/metabolism
PMC - PMC6151102
OTO - NOTNLM
OT  - anemia
OT  - chronic kidney disease
OT  - hypoxia-inducible factor stabilizer
OT  - meta-analysis
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/10/03 06:00
MHDA- 2018/12/26 06:00
PMCR- 2018/09/18
CRDT- 2018/10/02 06:00
PHST- 2018/10/02 06:00 [entrez]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2018/12/26 06:00 [medline]
PHST- 2018/09/18 00:00 [pmc-release]
AID - dddt-12-3003 [pii]
AID - 10.2147/DDDT.S175887 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2018 Sep 18;12:3003-3011. doi: 10.2147/DDDT.S175887. 
      eCollection 2018.